Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Syndax (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax (Nasdaq: SNDX) announced that CEO Michael A. Metzger will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 11:15 a.m. ET.
A live webcast will be available in the company’s Investor section at www.syndax.com, and a replay will be posted for a limited time.
Details
News Market Reaction – SNDX
On Dec 1, the day this news came out, SNDX closed 3.53% below the previous close.
Data tracked by StockTitan Argus for the Dec 1 session.
Key Figures
- Conference edition
- 8th Annual
- Evercore Healthcare Conference
- Conference date
- December 4, 2025
- Scheduled fireside chat
- Event time
- 11:15 a.m. ET
- Start time of fireside chat
Historical Context
-
Multiple positive Revuforj data sets presented across acute leukemia settings.
-
New hire inducement stock options under 2023 Inducement Plan.
-
CEO scheduled for Evercore Healthcare Conference fireside chat webcast.
-
Equity awards to four new employees under inducement plan.
-
3Q25 results with Revuforj FDA approval and growing prescriptions.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.
A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.